17817-31-1
![17817-31-1 结构式](/CAS/GIF/17817-31-1.gif)
基本信息
4',6,7-三羟基异黄酮
6,7,4'-TRIHYDROXYISOFLAVONE
DEMETHYLTEXASIN
TRIHYDROXYISOFLAVONE, 4',6,7-
TRIHYDROXYISOFLAVONE, 4',6,7-(RG)
6,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
物理化学性质
常见问题列表
CDK1
|
CDK2
|
PKC
|
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity . Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells. Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) .
Cell Viability Assay
Cell Line: | HCT-116 cells |
Concentration: | 0, 12.5, 25, 50 or 100 μM |
Incubation Time: | 24, 48 or 72 hours |
Result: | Inhibited anchorage-dependent and -independent growth of HCT-116 cells. |
Western Blot Analysis
Cell Line: | HCT-116 and DLD1 cells |
Concentration: | 0, 25, 50 or 100 μM |
Incubation Time: | 48 hours |
Result: | Inhibited CDK1,CDK2 expression. |
Cell Cycle Analysis
Cell Line: | HCT-116 cells |
Concentration: | 0, 25, 50 or 100 μM |
Incubation Time: | 24, 48 or 72 hours |
Result: | Induces cell cycle arrest of HCT-116 cells at S and G2/M phases. |
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system.
Animal Model: | Female athymic nude mice subcutaneously injected with HCT-116 cells |
Dosage: | 5 or 25 mg/kg |
Administration: | Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days |
Result: | Decreased tumor growth, volume and weight of HCT-116 xenografts. |